Patent Document ID: 7998674
Application ID: 12067549
Patent Flag: 1

Claim One:
1. A method of assessing the risk of distant metastasis in a patient having nasopharyngeal carcinoma comprising evaluating, in a sample from said patient, the expression profile of a combination of genes comprising (i) tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ); (ii) small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB); (iii) nuclear transport factor 2 (NUTF2); (iv) nucleoporin 205kDa (NUP205); (v) transketolase (TKT); (vi) guanine monphosphate synthetase (GMPS); (vii) chaperonin containing TCP1, subunit 3 γ (CCT3); (viii) t-complex 1 (TCP1); (ix) hypothetical protein FLJ12671 (FLJ12671); (x) poly(A) binding protein, cytoplasmic 1 (PABPC1); (xi) IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2); (xii) UMP-CMP kinase (UMP-CMPK); (xiii) elongation factor Tu GTP binding domain containing 1 (EFTUD1); (xiv) eukaryotic translation initiation factor 3, subunit 12 (EIF3S12); (xv) Tax1 (human T-cell leukemia virus type I) binding protein 1 (TAX1BP1); (xvi) dynein, cytoplasmic, light polypeptide 2A (DNCL2A); (xvii) AP2 associated kinase 1 (AAK1); (xviii) phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA); (xix) ARF GTPase-activating protein (FLJ00312); (xx) recombining binding protein suppressor of hairless (RBPSUH); (xxi) interferon gamma receptor 2 (IFNGR2); (xxii) splicing factor, arginine/serine-rich 4 (FLJ11021); (xxiii) non-POU domain containing, octamer-binding (NONO); (xxiv) survival of motor neuron protein interacting protein 1(SIP1); (xxv) ubiquitin protein ligase E3A (UBE3A); (xxvi) eukaryotic translation initiation factor 5A (EIF5A); (xxvii) c-mer proto-oncogene tyrosine kinase (MERTK); (xxviii) SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2); (xxix) Radixin (RDX); (xxx) heterogeneous nuclear ribonucleoprotein R (HNRPR); (xxxi) DnaJ (Hsp40) homolog, subfamily A, member 2 (DNAJA2); (xxxii) DnaJ (Hsp40) homolog, subfamily A, member 1(DNAJA1); (xxxiii) CDNA FLJ34482 fis, clone HLUNG2004067 (AP!GBP1); (xxxiv) F-box protein 7 (FBXO7); (xxxv) KIAA0962 protein (KIAA0962); (xxxvi) trinucleotide repeat containing 6B (TNRC6B); (xxxvii) chromosome 11 open reading frame2 (C11orf2); (xxxviii) additional sex combs like 2 (ASXL2); (xxxix) apolipoprotein E (APOE); (xl) ADP-ribosylation factor GTPase activating protein 3 (ARFGAP3); (xli) SH3 domain binding glutamic acid-rich protein like 3 (SH3BGRL3); (xlii) ATP synthase, H+transporting, mitochondrial F0 complex, subunit e (ATP5I); (xliii) sterol carrier protein 2 (SCP2); (xliv) apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C (APOBEC3C); (xlv) B-cell translocation gene 1, anti-proliferative (BTG1); (xlvi) golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1); (xlvii) chromosome 22 open reading frame 9 (C22orf9); (xlviii) Nijmegen breakage syndrome 1 (NBS1); (xlix) eukaryotic translation elongation factor 1 alpha 1 (EEF1A1); (l) thioredoxin reductase 1 (TXNRD1 ); (li) inositol polyphosphate-5 -phosphatase, 40 kDa (INPP5 A); (lii) solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 (SLC7A1); (liii) IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2); (liv) glutamyl-prolyl-tRNA synthetase (EPRS); (lv) chaperonin containing TCP1, subunit 2 β (CCT2); (lvi) chaperonin containing TCP1, subunit 1 α (TCP1); (lvii) anaphase promoting complex subunit 5 (ANAPC5); (lviii) nucleolar guanine nucleotide binding protein-like 2 (GNL2); and (lix) RNA binding motif protein 28 (RBM28).